Maryland Capital Advisors’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.3K Buy
+158
New +$14.1K 0.01% 188
2025
Q4
$12.3K Hold
155
﹤0.01% 193
2025
Q3
$11.7K Sell
155
-92
-37% -$6.3K ﹤0.01% 184
2025
Q2
$17K Hold
247
0.01% 171
2025
Q1
$16.7K Hold
247
0.01% 162
2024
Q4
$11.1K Sell
247
-30
-11% -$1.68K 0.01% 182
2024
Q3
$17.4K Sell
277
-56
-17% -$3.27K 0.01% 171
2024
Q2
$19.7K Sell
333
-45
-12% -$2.81K 0.01% 162
2024
Q1
$30.1K Hold
378
0.02% 133
2023
Q4
$29.8K Hold
378
0.02% 127
2023
Q3
$26.4K Hold
378
0.02% 128
2023
Q2
$26.1K Hold
378
0.02% 130
2023
Q1
$28.1K Hold
378
0.02% 123
2022
Q4
$35.2K Hold
378
0.03% 115
2022
Q3
$36K Hold
378
0.04% 101
2022
Q2
$35K Hold
378
0.04% 106
2022
Q1
$38K Hold
378
0.03% 106
2021
Q4
$39K Buy
+378
New +$34.9K 0.03% 102

Other funds holding CVS

Maryland Capital Advisors's CVS Position: Q2 2026 in Review

Maryland Capital Advisors opened a new position in CVS Health (CVS) in Q2 2026: 158 shares worth $16.3K. The stake represents 0.01% of the portfolio and ranks #188 among its holdings. This is a return to the name: Maryland Capital Advisors previously reported a position in CVS as recently as Q4 2025.

Maryland Capital Advisors first reported a position in CVS in Q4 2021 and has held it in 18 quarters since. The position peaked at $39K in Q4 2021. 937 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • Maryland Capital Advisors held 158 shares of CVS Health worth $16.3K as of Q2 2026.
  • CVS Health was a new Maryland Capital Advisors position in Q2 2026.
  • CVS Health made up 0.01% of Maryland Capital Advisors's portfolio in Q2 2026, its #188 holding.
  • Maryland Capital Advisors first reported a position in CVS Health in Q4 2021 and has held it in 18 quarters since.
  • Maryland Capital Advisors's CVS Health position peaked at $39K in Q4 2021.
  • 937 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on Maryland Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.